Abstract
To the Editor.— The Food and Drug Administration has recently stated that unless further information is made available regarding the efficacy of the oral form of edetate calcium disodium (EDTA) that after six months, this form will be removed from the market. Recently, during the screening of six workers in a stained glass window factory, three were found to have elevated blood lead levels (> 60μg/100 ml). Since two of these three patients' blood levels were only slightly elevated (81 μg/ 100 ml), each was treated with an oral course of edetate trisodium (Versenate Sodium), 4 gm daily for five days, with reduction of blood lead levels to normal. (The third case with much higher levels was treated parenterally.) Because of other experience 1-6 which would favor the efficacy of oral administration of EDTA by varied criteria, it appears to us that the 6-month period is inappropriately short to obtain sufficient
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
